Kintor Pharmaceutical Limited (KNTPF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -387.58 Million | -961.26 Million | -1.05 Billion | -380.88 Million | -228.04 Million | -114.86 Million |
| Net Income | -1.06 Billion | -953.28 Million | -842.09 Million | -508.22 Million | -232.57 Million | -108.48 Million |
| Depreciation & Amortization | 18.97 Million | 18.38 Million | 10.51 Million | 6.5 Million | 4.66 Million | 2.44 Million |
| Deferred income taxes | - | -95.63 Thousand | 37.01 Million | 112.6 Million | - | - |
| Stock-based compensation | 22.98 Million | 95.63 Million | 37.34 Million | 28.15 Million | - | - |
| Change in working capital | -96.48 Million | -197.95 Million | -284.58 Million | -12.87 Million | 145 Thousand | -3.72 Million |
| Other non-cash items | -3.38 Million | 171.58 Million | -9.55 Million | -7.04 Million | -278 Thousand | -5.1 Million |
| Investing Cash Flow | 3.27 Million | 67.19 Million | 92 Million | -439.72 Million | -7.01 Million | -64.74 Million |
| Investments in PPE | -2.72 Million | -27.64 Million | -105.74 Million | -96.16 Million | -74.12 Million | -19.41 Million |
| Acquisitions | - | -18.51 Million | -25.63 Million | 27.12 Million | -6.88 Million | 577 Thousand |
| Investment purchases | -137.09 Million | -220.7 Million | -515.4 Million | -733.69 Million | -55 Million | -221 Million |
| Sales/Maturities of investments | 136.25 Million | 337.05 Million | 710.94 Million | 388.51 Million | 55.57 Million | 241.48 Million |
| Other Investing Activities | 5.21 Million | -2.99 Million | 27.84 Million | -25.51 Million | 73.41 Million | -66.39 Million |
| Financing Cash Flow | -33.46 Million | 815.75 Million | 857.41 Million | 1.78 Billion | 295.85 Million | 303.93 Million |
| Debt repayment | -29.4 Million | -48.4 Million | -83.6 Million | -79.2 Million | -65 Million | -55 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -40.87 Thousand | - |
| Common Stock Issuance | 755 Thousand | 698.76 Million | 951.97 Million | 1.65 Billion | - | - |
| Other Financing Activities | 737.00 | 165.38 Million | -10.95 Million | 206.75 Million | 360.85 Million | 358.93 Million |
| Accounts receivables | 7623.00 | 94.23 Thousand | -86.03 Thousand | -13.02 Thousand | -10.69 Thousand | -10.83 Thousand |
| Accounts payables | - | -94.23 Thousand | 86.03 Thousand | - | - | - |
| Inventory | -376 Thousand | -345.12 Million | -351.36 Million | - | - | - |
| Other working capital | 3405.00 | 147.17 Million | 66.77 Million | -12.86 Million | 155.69 Thousand | -4941.00 |
| Cash at beginning of period | 864.47 Million | 926.33 Million | 1.06 Billion | 195.53 Million | 137.51 Million | 13.19 Million |
| Cash at end of period | 444.02 Million | 864.47 Million | 926.33 Million | 1.06 Billion | 195.53 Million | 137.51 Million |
| Capital Expenditure | -2.72 Million | -27.64 Million | -105.74 Million | -96.16 Million | -74.12 Million | -19.41 Million |
| Effect of forex changes on cash | -2.67 Million | 16.45 Million | -36.41 Million | -90.53 Million | -2.77 Million | - |
| Net cash flow / Change in cash | -420.44 Million | -61.86 Million | -138.35 Million | 869.15 Million | 58.01 Million | 124.32 Million |
| Free Cash Flow | -390.3 Million | -988.9 Million | -1.15 Billion | -477.04 Million | -302.16 Million | -134.28 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4918.75 | -4950.70 | -1.06 Billion | -117.38 Million | -58.12 Thousand | -30.6 Million |
| Depreciation & Amortization | 601.32 | 605.22 | 18.97 Million | 1.28 Million | 637.79 | 1.39 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 316.48 | 318.54 | 22.98 Million | - | -778.46 | - |
| Change in working capital | - | - | -96.48 Million | - | 729.49 | - |
| Other non-cash items | -3612.57 | -3636.04 | -3.38 Million | 96.01 Million | 45.63 Thousand | 1.35 Million |
| Investing Cash Flow | -46.78 | -47.09 | 3.27 Million | -293.87 Thousand | 207.92 | -170.38 Thousand |
| Investments in PPE | -33.85 | -34.07 | -2.72 Million | -300.03 Thousand | -150.25 | -76.32 Thousand |
| Acquisitions | 7630.50 | - | - | 666.26 | - | 28.27 Thousand |
| Investment purchases | -13.87 Thousand | - | -137.09 Million | 888.45 Thousand | - | -19.78 Million |
| Sales/Maturities of investments | - | - | 136.25 Million | -882.96 Thousand | - | 19.65 Million |
| Other Investing Activities | -12.93 | -13.02 | 5.21 Million | - | 358.17 | - |
| Financing Cash Flow | -1023.82 | -1030.47 | -33.46 Million | -9.93 Million | -4800.78 | 5.28 Million |
| Debt repayment | -1.77 Million | - | -29.4 Million | -9.62 Million | - | -5.54 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 49.39 Thousand | - | 755 Thousand | 11.46 Thousand | - | 92.62 Thousand |
| Other Financing Activities | -1023.82 | -1030.47 | 737.00 | - | -4800.78 | -346.83 Thousand |
| Accounts receivables | - | - | 7623.00 | - | 522.05 | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | -376 Thousand | - | -25.75 | - |
| Other working capital | - | - | 3405.00 | - | 233.19 | - |
| Cash at beginning of period | 62.85 Million | - | 864.47 Million | 95.94 Million | 95.19 Thousand | 125.14 Million |
| Cash at end of period | 44.44 Million | -8645.25 | 444.02 Million | 62.85 Million | 78.3 Thousand | 95.94 Million |
| Capital Expenditure | -33.85 | -34.07 | -2.72 Million | -300.03 Thousand | -150.25 | -76.32 Thousand |
| Effect of forex changes on cash | 94.67 | 95.28 | -2.67 Million | -923.21 Thousand | -399.33 | -3.66 Million |
| Net cash flow / Change in cash | -18.41 Million | -8645.25 | -420.44 Million | -33.08 Million | -16.89 Thousand | -29.19 Million |
| Free Cash Flow | -7647.37 | -7697.04 | -390.3 Million | -22.96 Million | -12.05 Thousand | -30.71 Million |
POLA
MGRX
GOCLCORP
INDX
BTML
SIKA